Quantcast
Home > Quotes > OPTN
OPTN

OptiNose, Inc. Common Stock (OPTN) Quote & Summary Data

$7.4
*  
0.25
3.5%
Get OPTN Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading OPTN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
28.5
Today's High / Low
$ 7.43 / $ 7.06
Share Volume
217,836
50 Day Avg. Daily Volume
224,384
Previous Close
$ 7.15
52 Week High / Low
$ 30 / $ 5.66
Market Cap
305,083,722
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.70
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.56

Intraday Chart

Shares Traded

Share Volume:
217,836
50 Day Avg. Daily Volume:
224,384

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.70

Trading Range

The current last sale of $7.40 is 30.74% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 7.43 $ 30
 Low: $ 7.06 $ 5.66

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. Our lead product, XHANCETM (fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing our proprietary Optinose Exhalation Delivery System, or EDS, that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. Chronic rhinosinusitis is a serious nasal inflammatory disease that is currently treated using therapies, such as intranasal steroids, or INS, that have significant limitations.  ... More ...  


Risk Grade

Where does OPTN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.19
Open Date:
Feb. 15, 2019
Close Price:
$ 7.40
Close Date:
Feb. 15, 2019

Consensus Recommendation

Analyst Info